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IMPORTANCE Chronic fatigue syndrome (CFS) is a disabling condition with unknown disease
mechanisms and few treatment options.
OBJECTIVE To explore the pathophysiology of CFS and assess clonidine hydrochloride
pharmacotherapy in adolescents with CFS by using a hypothesis that patients with CFS have
enhanced sympathetic activity and that sympatho-inhibition by clonidine would improve
symptoms and function.
DESIGN, SETTING, AND PARTICIPANTS Participants were enrolled from a single referral center
recruiting nationwide in Norway. A referred sample of 176 adolescents with CFS was assessed
for eligibility; 120 were included (34males and 86 females; mean age, 15.4 years). A volunteer
sample of 68 healthy adolescents serving as controls was included (22males and 46 females;
mean age, 15.1 years). The CSF patients and healthy controls were assessed cross-sectionally
at baseline. Thereafter, patients with CFS were randomized 1:1 to treatment with low-dose
clonidine or placebo for 9 weeks andmonitored for 30weeks; double-blinding was provided.
Data were collected fromMarch 2010 until October 2012 as part of the Norwegian Study of
Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial.
INTERVENTIONS Clonidine hydrochloride capsules (25 μg or 50 μg twice daily for body weight
<35 kg or >35 kg, respectively) vs placebo capsules for 9 weeks.
MAIN OUTCOMES ANDMEASURES Number of steps per day.
RESULTS At baseline, patients with CFS had a lower number of steps per day (P < .001), digit
span backward score (P = .002), and urinary cortisol to creatinine ratio (P = .001), and a
higher fatigue score (P < .001), heart rate responsiveness (P = .02), plasma norepinephrine
level (P < .001), and serum C-reactive protein concentration (P = .04) compared with healthy
controls. There were no significant differences regarding bloodmicrobiology evaluation.
During intervention, the clonidine group had a lower number of steps per day (mean
difference, −637 steps; P = .07), lower plasma norepinephrine level (mean difference, −42
pg/mL; P = .01), and lower serum C-reactive protein concentration (mean ratio, 0.69; P = .02)
compared with the CFS placebo group.
CONCLUSIONS AND RELEVANCE Adolescent CFS is associatedwith enhanced sympathetic
nervous activity, low-grade systemic inflammation, attenuated hypothalamus-pituitary-
adrenal axis function, cognitive impairment, and large activity reduction, but not with
commonmicroorganisms. Low-dose clonidine attenuates sympathetic outflow and systemic
inflammation in CFS but has a concomitant negative effect on physical activity; thus,
sympathetic and inflammatory enhancement may be compensatory mechanisms. Low-dose
clonidine is not clinically useful in CFS.
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C hronic fatigue syndrome (CFS) is characterized by un-explained, long-lasting, disabling fatigue accompa-nied by pain, cognitive impairment, orthostatic intol-
erance, and other symptoms.1,2 Chronic fatigue syndrome is
an important cause of disability among adolescents andmay
have detrimental effects on psychosocial and academic
development3 as well as family functioning.4 The adolescent
CFS prevalence is estimated at 0.1% to 1.0%.5-7 Cognitive be-
havioral therapy has a beneficial effect,8 but no safe and ef-
fective pharmacotherapy has been documented.
The pathophysiology of CFS remains poorly understood.
Previous adolescent studies9-11 reported enhanced sympa-
thetic and attenuated parasympathetic cardiovascular ner-
vous activity, possibly explaining symptoms and disability.12
Low-grade systemic inflammation13,14 and attenuation of the
hypothalamus-pituitary-adrenal axis 15,16 havealsobeendocu-
mented in some studies.Neuropsychological studies17-19 sug-
gest slight impairmentsof executive control functions; thede-
tails remain to be explored.
One study20 suggested that all of these features might be
attributed toapersistent stress responseor“sustainedarousal”
(Supplement [eFigure 1]). Thismodel complieswithotherCFS
models21 and rests on contemporary stress theories.22,23 Sus-
tained arousal might be caused by infections,24 which seem
tobeprecipitating factors inCFS.25,26However, theprecise role
of microorganisms in CFS remains unclear.
Clonidinehydrochloride is a centrally actingagonist to the
α2-adrenergic receptor.27 Clonidine inhibits sympathetic ner-
vous activity and enhances parasympathetic nervous activ-
ity, thereby lowering heart rate and blood pressure.28 In addi-
tion, clonidinemight have anti-inflammatory properties,29 as
well as a beneficial effect on executive functions during con-
ditions of high arousal in primates,30 in line with a previous
CFS study.31
The aim of the present study was 2-fold: (1) explore the
pathophysiology of CFS and (2) assess the effect of low-dose
clonidine treatment in adolescent CFS.Wehypothesized that
enhanced sympathetic activity is an important part of CFS
pathophysiology and that sympatho-inhibition by clonidine
would improve symptoms and function.
Methods
PatientsWith CFS
The Department of Paediatrics at Oslo University Hospital is
a national referral center in Norway for young patients with
CFS. For the present study, all 20 hospital pediatric depart-
ments in Norway, as well as primary care pediatricians and
general practitioners, were invited to refer patients with CFS
aged 12 to 18 years consecutively to our department. The
referring units were required to confirm that the patient did
not have any medical or psychiatric disorder that might
explain the fatigue and that they had experienced no con-
current demanding life event.
In agreement with clinical guidelines,2,32 we applied a
broad case definition requiring 3months of unexplained dis-
abling, chronic/relapsing fatigue of new onset (Supplement
[eMethods]). We did not require that patientsmeet any other
accompanying symptom criteria.
Healthy Controls
A group of healthy adolescents with a comparable distribu-
tion of sex and age were recruited from local schools to serve
as a control group for the cross-sectional comparison. Con-
trols were not matched to cases on any variable. No chronic
disease and no regular use of pharmaceutical agents were
allowed.
Study Design
This study is part of theNorCAPITAL-project (TheNorwegian
Study of Chronic Fatigue Syndrome in Adolescents: Patho-
physiologyand InterventionTrial) (Supplement [eFigure2and
eAppendix]),whichhas been approvedby theNorwegianNa-
tional Committee for Ethics inMedical Research and theNor-
wegianMedicinesAgency (Supplement [eMethods]).Datawere
collected between March 1, 2010, and October 15, 2012. Writ-
ten informed consent was obtained from all participants or
from parents or next of kin if required. Each participant re-
ceived a gift certificate worth NKr 200 after each completed
in-hospital assessment.
This study combined a cross-sectional and a randomized
clinical design: (1) patientswith CFS and healthy controls un-
derwentabaseline investigationalprogramatour researchunit,
and (2) patientswithCFSwere randomized to9weeksof treat-
ment with oral clonidine capsules or placebo capsules in a 1:1
ratiobyusinga computer-based routine for stratified random-
ization (blocksize:4) (Figure1).Adiseasedurationof 18months
(themediandisease duration in a previous follow-up study33)
served as the stratification criterion.
The intervention part of the trial followed a modified in-
tention-to-treat approach.34 Pharmacy routines required ran-
domization tobecarriedoutat least 1daybefore thestudydrug
wasdispensed toeachpatient.However, a separate clinical en-
counter to assess eligibility was not feasible. Instead, pa-
tients fulfilling prespecified criteria (Supplement [eTable 1])
were consecutively randomized after receipt of the referral
form (Supplement [eMethods]). A few weeks after random-
ization, patients were clinically assessed at our research unit
(byD.S.orE.F.), afterwhichadecisiononenrollmentwasmade
(Supplement [eTable 2]). Special attention was directed to-
ward excluding patients with depression as a primary cause
of fatigue.
Outcomewasassessedbyan investigationalprogramiden-
tical to the baseline program at weeks 8 and 30. Patients and
researchers were blinded to treatment allocation at all stages
(Supplement [eTable 7]).
Investigational Program
A 1-day in-hospital assessment included clinical examina-
tion, blood sampling (antecubital venous puncture), 20°
head-up tilt test, and cognitive tests and always began
between 7:30 AM and 9:30 AM (Supplement [eMethods]). All
participants were instructed to fast overnight and abstain
from tobacco products and caffeine for at least 48 hours, to
bring a morning spot urine sample in a sterile container, and
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to apply the local anesthetic lidocaine, 2.5%, and prilocaine,
2.5% (EMLA; AstraZeneca), on the skin in the antecubital
area 1 hour before the blood sampling. At week 8, patients
with CFS were told to postpone taking their prescribed
morning dose of the study drug until after blood sampling
and the head-up tilt test. All procedures were carried out in a
quiet room in a fixed sequence and by the same 3 research-
ers (D.S., E.F., and A.W.).
After the in-hospitalassessment,dailyphysicalactivitywas
monitored during 7 consecutive days using an accelerometer
device (activPAL; PAL Technologies Ltd). In addition, a self-
administered questionnaire was completed.
Intervention
Tablets containing 25μg of clonidinehydrochloride (Catapre-
san; Boehringer Ingelheim) were enclosed in orange opaque,
demolition-resistant lactose capsules (Apoteket Produktion
andLaboratorier). Empty capsuleswereused asplacebo com-
parators.
Clonidine lowers blood pressure dose dependently,35,36
possibly increasing the risk of adverse effects in patientswith
CFS who already experience orthostatic intolerance.9 There-
fore, clonidine dosages were chosen to yield plasma concen-
trations within the lower range of what is considered clini-
cally effective.Basedonapreviouspilot study,37 the following
algorithmwas used:
• Patient weight greater than 35 kg: 2 capsules twice daily for
8 weeks (ie, clonidine, 50 μg twice daily, in the intervention
group); and
• Patientweight less than35kg: 1capsule twicedaily for8weeks
(ie, clonidine, 25 μg twice daily, in the intervention group).
Therapy was initiated 1 week after the baseline investi-
gational program. One-half of the dose was given during the
first 3 days to minimize introductory adverse effects. After 8
weeks of the full dose, the dose was halved for 1 additional
week to avoid rebound effects, after which treatment was
discontinued.
At therapy initiation, eachpatientwas suppliedwith ade-
finednumber of capsules. The residual number atweek8was
counted, andan indexof adherencewas calculated.Clonidine
plasma concentration was measured at weeks 3 and 8.
Outcomes
Theprimary efficacy endpointwas themeannumber of steps
per day, obtained by an accelerometer recording (Supple-
ment [eMethodsandeTable 3]). Secondaryefficacyendpoints
(Supplement [eTable 4]) were
• Functional Disability Inventory total sum score,
• Chalder Fatigue Questionnaire total sum score,
• Karolinska Sleep Questionnaire insomnia score,
• CFS symptom inventory hypersensitivity score,
• Brief Pain Inventory average pain score,
• Digit span backward test total sum score,
• Heart rate responsiveness during head-up tilt test,
• Plasma norepinephrine concentration,
• Urinary free cortisol to creatinine ratio, and
• Serum C-reactive protein (CRP) concentration.
Adverse Events
Supine andupright bloodpressure andheart ratewere consid-
ered the most important safety end points. A questionnaire
chartedthefrequenciesof21possibleadverseeffectsofclonidine
ona1 to5Likertscale (rangingfromnever/rarelypresent topres-
ent all of the time) andwas completed by interview atweek 8.
In addition, patients were routinely interviewed by telephone
about adverse effects at weeks 2, 4, and 6.
Statistical Analysis
Themean (SD) number of steps per day approximates 10 000
(4000) in healthy adolescents.38 An increment of 2500 steps
per day for the CFS clonidine groupwas considered clinically
Figure 1. Flowchart of the Randomized Clinical Trial Section of the Study
176 Adolescents with CFS 
assessed for eligibility
25 Not eligible for randomization 
6
6
5
5
3
Use of other pharmaceuticals
Uncertain diagnosis
Older than age limit
Declined participation
Spontaneous recovery
151 Fulfilled criteria for 
randomization
76 Clonidine 75 Placebo
16 Not included
7
6
3
Declined participation
Met exclusion criteria
Spontaneous recovery
120 Fulfilled inclusion criteria 
and started treatment
15 Not included
9
4
2
Met exclusion criteria
Declined participation
Alternative treatment
60 Clonidine 60 Placebo
5 Dropouts
2
1
1
1
Headache
Syncope
Declined to take 
capsules
Declined participation
9 Dropouts
5
1
1
1
1
Declined participation
Declined to take 
capsules
Suspected suicidality
Abdominal discomfort
Intercurrent illness
55 Completed clonidine 
intervention at week 8
51 Completed placebo 
intervention at week 8
1 Dropout: declined 
participation
2 Dropouts: declined 
participation
54 Completed investigational 
program at week 30
49 Completed investigational 
program at week 30
A total of 176 patients with chronic fatigue syndrome (CFS) were assessed for
eligibility, 151 fulfilled criteria for randomization and 120 fulfilled the inclusion
criteria and started treatment: 60were allocated to clonidine, and 60 to
placebo. At week 8, a total of 55 patients had completed the clonidine
intervention and 51 had completed the placebo intervention. At week 30, a total
of 54 vs 49 patients, respectively, had completed the investigational program.
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significant, as suggested fromanadult study.39Thepower cal-
culation suggested that a total of 106 patients was to be in-
cluded (significance level, .05, power, 0.9) (Supplement [eRe-
sults]). The drop-out rate was estimated at 10%, yielding a
target enrollment of 120 patients.
Patients with CFS were compared with healthy controls
by applying t, Mann-Whitney, χ2, or Fisher exact tests as
appropriate. The outcome of clonidine intervention was
assessed by general linear models (analysis of covariance),
adjusting for baseline values and disease duration; we per-
formed both modified intention-to-treat analyses and per-
protocol analyses (Supplement [eTable 9]). Separate tests
were conducted for all outcome variables at weeks 8 and 30,
and a multiple imputation procedure was used to handle
missing observations. The net intervention effect was calcu-
lated from the parameters of the fitted general linear model.
Differential effects in subgroups were explored by including
relevant interaction terms. In the clonidine group, dose-
response relationships were explored by multiple linear
regression analyses.
Statistical software (SPSS; SPSS Inc.)wasused for all analy-
ses. All testswere carried out 2-sided, andP ≤ .05was consid-
ered statistically significant. No correction for multiple com-
parisons was applied.
Results
Study Populations
A total of 176 adolescents with CFS were referred and as-
sessed for eligibility (Figure 1). Of these, 151 fulfilled random-
ization criteria and 120 fulfilled the inclusioncriteria (34males
and 86 females; mean age, 15.4 years), completed the inves-
tigational program, and started treatment (60 in each treat-
ment group). Of the 120 patients, 88 individuals (73.3%) sat-
isfied the Fukuda criteria from the International Chronic
Fatigue SyndromeStudyGroup,1 and49patients (40.8%)had
depressive symptoms indicating a possible comorbid mood
disorder.40
A total of 68 healthy individuals were included as a con-
trol group (22males 46 females;mean age, 15.1 years). Thirty-
nineof these adolescents completeda full investigational pro-
gram, and 29 underwent only laboratory analyses.
Healthy Control Comparisons
Compared with healthy controls, patients with CFS had sig-
nificantly lower number of steps per day, insomnia score,
digit span backward score, and urinary cortisol to creatinine
ratio. In addition, patients with CFS had higher disability
score, fatigue score, average pain score, hypersensitivity
score, heart rate responsiveness, and plasma norepinephrine
and serum CRP concentration levels (Table 1). All differences
remained significant when controlling for depressive symp-
toms except the digit span backward score (P = .06) and
serum CRP (P = .27). Supine and upright heart rates were
higher in the CFS group, whereas blood pressures were simi-
lar. No significant differences were found for sex, age, body
mass index, family characteristics, and blood hematology,
biochemistry, and microbiology studies (Table 1 and Supple-
ment [eTable 8]).
Intervention
Fourteen patients with CFS dropped out before week 8 (5 in
the clonidine group, 9 in the placebo group), and an addi-
tional 3 withdrew prior to week 30 (Figure 1 and Supplement
[eTable5andeTable6]).Themean indexofadherencewas93%
(clonidine group) and 92% (placebo group). At week 8 in the
clonidine group, themean plasma concentration of clonidine
was 0.24 μg/L. The estimated mean steady-state concentra-
tion (trough value) was 0.23 μg/L.
Outcome
During intervention, thenumber of steps per day increased in
the placebo group but not in the clonidine group, resulting in
an estimated mean difference of −637 steps (P = .07) at week
8 (Table2andFigure2). PlasmanorepinephrineandserumCRP
levels decreased in the clonidine group (meandifference, −42
pg/mL;P = .01;mean ratio, 0.69;P = .02; respectively) (to con-
vert norepinephrine values to picomoles per liter,multiply by
5.914). No other interventional effects on efficacy variables
were found. At week 8, the clonidine group had slightly but
significantly lower supine and upright heart rates compared
with the placebo group (P = .03 and P = .03, respectively). No
other effects on cardiovascular safety end points were dem-
onstrated.Atweek 30, the 2 groupswere similar across all end
points except for lower heart rate responsiveness in the
clonidine group (P = .03). The results of per-protocol analy-
ses were closely similar to the modified intention-to-treat
analyses (Supplement [eTable 9]).
Clonidine plasma concentration was negatively associ-
ated with the number of steps per day and positively associ-
ated with the fatigue score (Supplement [eTable 10]). No
other dose-response relationships were detected apart from
a negative association between the estimated steady-state
concentration and the insomnia score (ie, insomnia prob-
lems increased with concentrations). No differential out-
come related to the 2 predefined subgroups (adherence to
the Fukuda criteria and presence of depressive symptoms)
was found.
Adverse Events
In the clonidine group, one patient fainted and another pa-
tient was found to have a peptic duodenal ulcer immediately
after the intervention period. Sleepiness and dizziness when
risingwere significantlymore common in the clonidinegroup,
but there was no significant difference in the total number of
self-reported adverse effects (Supplement [eTable 11]).
Discussion
There were 2 primary findings of this study. First, adolescent
CFS is associated with enhanced sympathetic nervous activ-
ity, low-grade systemic inflammation, attenuated hypothala-
mus-pituitary-adrenal axis function, slight cognitive impair-
ment, and large activity reduction, but not with common
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microorganisms. Second, clonidine attenuates sympathetic
outflowandsystemic inflammation inCFS,buthas a concomi-
tant negative effect on physical activity.
Sympathetic Nervous Activity
Comparedwith the controls, patientswith CFS had increased
levels of plasmanorepinephrine, aswell as a higher heart rate
(supine and upright) and heart rate responsiveness, indicat-
ing sympathetic enhancement. Increasedplasmanorepineph-
rine isaconspicuous finding,confirmingprevious results,11 and
is consistent with a report of high plasma neuropeptide Y
levels.41 Sympathetic enhancement might result from physi-
cal deconditioning. In the present study, however, neither
plasmanorepinephrine levelnorheart rate responsivenesswas
associated with the number of steps per day in patients with
CFS (Supplement [eTable 12]).
InpatientswithCFS, loweringnorepinephrine levelswith
clonidinewas associatedwith lowerphysical activity than the
activity with placebo. Thus, clonidine appeared to eliminate
a relatively strong placebo effect, and the observed differ-
ences resolved when the study drug was discontinued. A re-
cent study42 suggested that sympathetic activation is a pre-
dictor of the placebo response.
Inflammation
Clonidine loweredbothplasmanorepinephrineandserumCRP
levels in patientswith CFS, suggesting that enhanced sympa-
thetic nervous activity might be the cause of low-grade sys-
temic inflammation. Catecholaminergic stimulation of lym-
phocytes has been shown43 to promote secretion of the
cytokine interleukin 6, which in turn enhances CRP synthe-
sis. Alternatively, the anti-inflammatory effect of clonidine
Table 1. Background Characteristics
Characteristic
Mean (SD)
P Value (CFS
Patients vs
Controls)a
CFS Patients, Baseline
Healthy
Controls
(n = 68)
Clonidine
Group
(n = 60)
Placebo
Group
(n = 60)
Sex, No. (%)
Male 13 (22) 21 (35) 22 (32) .56
Female 47 (78) 39 (65) 46 (68)
Age, y 15.2 (1.5) 15.5 (1.6) 15.1 (1.6) .18
BMI 21.6 (4.4) 21.5 (4.0) 20.6 (3.7) .12
Symptoms suggesting mood disorder, No. (%)
No 34 (57) 36 (60) 34 (92) <.001
Yes 26 (43) 23 (39) 3 (8)
Adheres to Fukuda criteria, No. (%)b
No 14 (24) 15 (26) NA
Yes 45 (76) 43 (74)
Disease duration, median (range), mo 17.5 (4-72) 18 (5-104) NA
Efficacy variables, baseline
No. of steps per day 4670 (2277) 4564 (2524) 10 302 (3667) <.001
FDI total sum score 24.0 (9.2) 23.1 (9.2) 1.6 (3.1) <.001
CFQ total sum score 19.1 (6.4) 19.2 (6.1) 9.3 (4.6) <.001
BPI average pain score 4.8 (2.1) 4.3 (2.1) 2.5 (1.8) <.001
KSQ insomnia score 3.4 (1.0) 3.5 (0.9) 4.9 (0.9) <.001
Symptom inventory hypersensitivity score 2.9 (1.2) 2.8 (1.3) 1.1 (0.2) <.001
Digit span backward total sum score 5.8 (1.9) 6.0 (2.0) 6.9 (2.0) .002
Heart rate responsiveness, beats/min 5.2 (3.8) 4.8 (4.8) 3.2 (3.4) .02
Plasma norepinephrine, pg/mL 343 (140) 327 (123) 251 (74) <.001
Urine cortisol to creatinine ratio, median (IQR),
μg to mg
13.5 (12.5) 9.3 (8.3) 17.0 (19.2) .001
Serum CRP, median (IQR), mg/L 0.50 (0.97) 0.39 (0.96) 0.35 (0.46) .04
Safety variables, baseline
Supine SBP, mm Hg 112 (10) 114 (9) 113 (7) .67
Supine DBP, mm Hg 62 (9) 65 (10) 63 (7) .50
Supine heart rate, beats/min 75 (13) 76 (13) 68 (11) .002
Upright SPB, mm Hg 116 (15) 117 (11) 117 (9) .64
Upright DPB, mm Hg 74 (11) 75 (12) 71 (9) .11
Upright heart rate, beats/min 95 (18) 94 (19) 86 (14) .003
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
BPI, Brief Pain Inventory; CFS, chronic
fatigue syndrome; CFQ, Chalder
Fatigue Questionnaire; CRP,
C-reactive protein; DBP, diastolic
blood pressure; FDI, Functional
Disability Inventory; IQR,
interquartile range; KSQ, Karolinska
Sleep Questionnaire; NA, not
applicable; SBP, systolic blood
pressure.
SI conversion factors: To convert CRP
to nanomoles per liter, multiply by
9.524; urine cortisol to creatinine
ratio to micromoles per mole,
multiply by 0.3122; norepinephrine to
picomoles per liter, multiply by 5.914.
a P values were based on χ2 test,
Fisher exact test, t test, or
Mann-Whitney test, as appropriate.
b Fukuda criteria are CFS diagnostic
criteria from the International
Chronic Fatigue Syndrome Study
Group.1
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Table 2. Outcome of Clonidine Intervention: Modified Intention-to-Treat Analysesa
Efficacy Variable Week 8 (During Treatment) Week 30 (After Treatment)
Steps per day, No.
Clonidine group, mean 4631 4682
Placebo group, mean 5212 4652
Difference (95% CI) −637 (−1328 to 53) 119 (−796 to 1035)
P value (clonidine vs placebo) .07 .80
FDI total sum score
Clonidine group, mean 21.4 17.5
Placebo group, mean 20.7 16.8
Difference (95% CI) 0.2 (−10.3 to 10.8) 0.2 (−13.3 to13.6)
P value (clonidine vs placebo) .97 .98
CFQ total sum score
Clonidine group, mean 17.9 11.1
Placebo group, mean 16.4 13.5
Difference (95% CI) 1.7 (−2.3 to 5.6) 0.5 (−14.7 to 15.7)
P value (clonidine vs placebo) .24 .95
BPI average pain score
Clonidine group, mean 4.1 3.8
Placebo group, mean 3.4 3.3
Difference (95% CI) 0.5 (−0.16 to 1.16) 0.4 (−0.4 to 1.1)
P value (clonidine vs placebo) .14 .32
KSQ insomnia score
Clonidine group, mean 3.7 3.6
Placebo group, mean 3.8 3.6
Difference (95% CI) 0.1 (−0.4 to 0.2) 0.1 (−0.3 to 0.4)
P value (clonidine vs placebo) .54 .74
Symptom inventory hypersensitivity score
Clonidine group, mean 2.6 2.6
Placebo group, mean 2.4 2.6
Difference (95% CI) 0.1 (−0.2 to 0.5) −0.03 (−0.4 to 0.3)
P value (clonidine vs placebo) .42 .84
Digit span backward total sum score
Clonidine group, mean 5.8 5.9
Placebo group, mean 6.2 6.7
Difference (95% CI) − 0.1 (−0.6 to 0.5) −0.5 (−1.2 to 0.1)
P value (clonidine vs placebo) .80 .10
Heart rate responsiveness, beats/min
Clonidine group, mean 5.0 4.2
Placebo group, mean 4.9 5.2
Difference (95% CI) −0.1 (−1.3 to 1.1) −1.5 (−2.8 to 0.1)
P value (clonidine vs placebo) .90 .03
Plasma norepinephrine, pg/mL
Clonidine group, mean 262 296
Placebo group, mean 288 298
Difference (95% CI) −42 (−75 to −9) −9 (−51 to 32)
P value (clonidine vs placebo) .01 .66
Urine cortisol to creatinine ratio, μg/dL to mg/dL
Clonidine group, mean 12.2 12.5
Placebo group, mean 13.5 12.8
Ratio (95% CI) 0.79 (0.59 to 1.01) 0.95 (0.68 to 1.33)
P value (clonidine vs placebo) .13 .77
(continued)
Research Original Investigation Clonidine in Adolescent Chronic Fatigue Syndrome
E6 JAMAPediatrics Published online February 3, 2014 jamapediatrics.com
Downloaded From: http://archpedi.jamanetwork.com/ by a Helsebiblioteket gir deg tilgang til JAMA User  on 02/10/2014
Copyright 2014 American Medical Association. All rights reserved.
might be the result of enhanced parasympathetic activity,28
which suppresses the transcription factor nuclear factor κB in
macrophages and thereby lowers secretion of proinflamma-
tory cytokines.44 Increasednuclear factor κBactivityhasbeen
reported45 in CFS.
The present study confirms findings from some
studies15,16 of low urinary free cortisol in CFS. Systemic
inflammation in CFS has been attributed to hypothalamus-
pituitary-adrenal axis attenuation.13 This possibility seems
less likely in light of the present results, because urinary free
cortisol concentration tended to decrease during clonidine
intervention.
Low-gradesystemic inflammationalsomightbecausedby
ongoingor reactivationof infections,but thepresentstudydoes
not suggest an increased presence of common microorgan-
isms in CFS, a finding that is consistent with other reports.46
However, our finding of elevated CRP levels in CFS might be
partly explained by the coexistence of depressive symptoms,
because controlling for such symptoms leveled out CRP dif-
ferences between patients and controls.
Hemodynamics
Clonidine did not lower blood pressure or heart rate respon-
siveness and had a minimal effect on supine and upright
heart rates. Furthermore, a dose-response relationship could
not be demonstrated. These findings contrast with those of
previous studies35,36 in which similar dosages and plasma
concentrations of clonidine had a significant and dose-
dependent effect on blood pressure and heart rate. A poten-
tial plasma-expanding effect of clonidine might offset blood
Table 2. Outcome of Clonidine Intervention: Modified Intention-to-Treat Analysesa (continued)
Efficacy Variable Week 8 (During Treatment) Week 30 (After Treatment)
Serum CRP, mg/L
Clonidine group, mean 0.55 0.85
Placebo group, mean 0.77 0.79
Ratio (95% CI) 0.69 (0.50 to 0.94) 1.1 (0.8 to 1.5)
P value (clonidine vs placebo) .02 .66
Safety Variables
Supine SBP, mm Hg
Clonidine group, mean 112 113
Placebo group, mean 110 113
Difference (95% CI) 1.5 (−0.93 to 4.0) 1.5 (−1.2 to 4.1)
P value (clonidine vs placebo) .22 .28
Supine DBP, mm Hg
Clonidine group, mean 61 60
Placebo group, mean 61 61
Difference (95% CI) 1.6 (−0.72 to 3.9) 0.8 (−2.0 to 3.5)
P value (clonidine vs placebo) .17 .59
Supine heart rate, beats/min
Clonidine group, mean 69 73
Placebo group, mean 73 72
Difference (95% CI) −3.0 (−5.8 to −0.3) 0.8 (−2.0 to 3.9)
P value (clonidine vs placebo) .03 .56
Upright SPB, mm Hg
Clonidine group, mean 115 117
Placebo group, mean 116 118
Difference (95% CI) −0.7 (−3.57 to 3.44) −0.2 (−3.7 to 3.4)
P value (clonidine vs placebo) .97 .92
Upright DPB, mm Hg
Clonidine group, mean 70 70
Placebo group, mean 70 70
Difference (95% CI) 0.6 (−2.9 to 4.2) 0.3 (−2.7 to 3.2)
P value (clonidine vs placebo) .72 .85
Upright heart rate, beats/min
Clonidine group, mean 90 94
Placebo group, mean 96 98
Difference (95% CI) −5.8 (−11.0 to −1.0) −3.4 (−8.9 to 2.0)
P value (clonidine vs placebo) .03 .22
Abbreviations: See Table 1.
SI conversion factors: To convert CRP
to nanomoles per liter, multiply by
9.524; urine cortisol to creatinine
ratio to micromoles per mole,
multiply by 0.3122; norepinephrine to
picomoles per liter, multiply by 5.914.
a All analyses were based onmultiple
imputation of missing values. Means
and differences at weeks 8 and 30
were estimated from the variables
of the general linear model. Model
diagnostics were performed by
visual inspection of residual plots.
For urine cortisol to creatinine ratio
and serum CRP, modeling was
performed on natural
log–transformed variables;
geometric means and ratios instead
of differences are reported.
Randomization was carried out
before enrollment; thus, not all
randomized patients received
treatment (Figure 1).
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pressure reduction, but a previous study47 and our own data
on body weight and hemoglobin concentration (Supplement
[eTable 13]) do not support this possibility. A more likely
explanation might be altered adrenergic receptor density,
which is consistent with a recent report48 of abnormal
α2-receptor protein transcription in CFS. Alteration of phar-
macodynamics might also explain the association between
high clonidine concentration and insomnia problems in the
present study despite the well-known sedative effect of
clonidine and the lack of clonidine’s effect on working
memory.31
Clinical Implications
Low-dose clonidine is not clinically useful in adolescent CFS,
and alternative therapeutic strategies should be explored.
The results further suggest that neither sympathetic
enhancement nor low-grade systemic inflammation contrib-
utes to symptoms and disability in CFS, as postulated in the
sustained arousal model.20 The differences between the
patients and the controls were small, especially for CRP lev-
els. Sympathetic enhancement and inflammation might
instead be compensatory mechanisms, because suppression
of these responses in the clonidine group was associated
with a poorer clinical outcome.
Strengths and Limitations
This studyhadgoodadherenceanda lowdrop-out rate, in line
withother studies in the field.8Thewide inclusioncriteria sug-
gest generalizability to thepopulationof adolescentswithCFS
referred to pediatric care. Because only 2 patients had dis-
ease duration between 3 and 6months, the results should be
generalizable to populations inwhichmore than 6months of
fatigue is required.
The single-center design and the fact that our inclusion
criteria are not identical to common international standards
might reduce generalizability. However, subgrouping
(Fukuda criteria and comorbid depressive symptoms) did
not suggest a differential response to the intervention. The
results might also apply to adults with CFS because previous
research does not suggest important differences in patho-
physiology.
The prevalence of comorbid depressive symptoms
among patients with CFS was higher than in a comparable
study.49 It is possible that we included some patients with
primary depression rather than CFS; ideally, a formal psychi-
atric interview should have been conducted. However, a
more likely explanation is low discriminant validity of the
applied depression inventory, because several single items
assess symptoms that are common in both depression
and CFS.40
Weuseda lowclonidinedosage, and the studywouldhave
benefited from a more thorough pilot study of dosage algo-
rithms. The negative effect of clonidine on physical activity
and fatiguemight be the result of pharmacologic effects other
than sympathetic/inflammatory attenuation. Because of the
multiple statistical tests used for analyses, P values close to
the limit of significance (P ≤ .05) should be interpreted with
caution.
Figure 2. Changes of Efficacy Variables During the Intervention Period
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Conclusions
Adolescent CFS is associated with enhanced sympathetic
nervous activity, attenuated hypothalamus-pituitary-adrenal
axis, low-grade systemic inflammation, slight cognitive
impairment, and large activity reduction, but not with com-
mon microorganisms. Sympathetic enhancement might
cause inflammation, but neither sympathetic enhancement
nor inflammation appears to contribute to physical disability
or fatigue. Low-dose clonidine is not a clinically useful
therapy in adolescent CFS; rather, it appears that the auto-
nomic and inflammatory processes that clonidine blocks may
have beneficial effects.
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